Featured Research

from universities, journals, and other organizations

Impact of race and health insurance on delays in breast cancer diagnosis and treatment in the District of Columbia

Date:
April 18, 2010
Source:
American Association for Cancer Research
Summary:
Race may play a larger role than previously thought when it comes to optimal diagnosis and treatment of black women with breast cancer.

Race may play a larger role than previously thought when it comes to optimal diagnosis and treatment of black women with breast cancer.

Researchers at The George Washington Cancer Institute, with funding from the National Cancer Institute, examined the effect of race and health insurance status on diagnostic and treatment delays over a 12-year period.

"We thought having health insurance would even the field. Insured black women should have had the same rapid evaluation as insured white women, but that was not the case in our study," said Heather Hoffman, Ph.D., assistant professor of epidemiology and biostatistics at The George Washington University School of Public Health and Health Services.

Hoffman and colleagues conducted a retrospective, cohort study of 581 women with breast cancer. Women were examined between 1997 and 2009 at seven hospitals and clinics in Washington, D.C.

Diagnostic delay time was defined as the number of days from abnormal screening to diagnosis, and treatment delay time was defined as the number of days from diagnosis to treatment initiation.

According to Hoffman, the goal was to identify risk factors associated with delays in diagnosis. They found the following:

  • insured black women and uninsured white women waited more than twice as long to reach their definitive diagnosis than insured white women;
  • lack of health insurance decreased the speed of diagnosis in white women, but having insurance did not increase the speed of diagnosis in black women; and
  • overall, black women waited twice as long as white women for treatment initiation following definitive diagnosis.

Based on the results of this study, the researchers suggested that outreach focus on all black women and uninsured white women to improve their diagnostic time, and the importance of medical follow-up should be explained to patients.

"Black women should be the focus of breast cancer screening outreach and follow-up because they experience greater delays in diagnosis and in treatment than white women, regardless of insurance status," said Hoffman. "We need to determine those barriers in insured black women and all uninsured women."

This research was recently presented at the American Association for Cancer Research 101st Annual Meeting 2010.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Impact of race and health insurance on delays in breast cancer diagnosis and treatment in the District of Columbia." ScienceDaily. ScienceDaily, 18 April 2010. <www.sciencedaily.com/releases/2010/04/100418215339.htm>.
American Association for Cancer Research. (2010, April 18). Impact of race and health insurance on delays in breast cancer diagnosis and treatment in the District of Columbia. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/04/100418215339.htm
American Association for Cancer Research. "Impact of race and health insurance on delays in breast cancer diagnosis and treatment in the District of Columbia." ScienceDaily. www.sciencedaily.com/releases/2010/04/100418215339.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins